DprE1-IN-25
CAS No. 1615713-87-5
DprE1-IN-25 ( MDK3875; MDK-3875; MDK 3875; DprE1-IN-2; DprE1IN2 )
Catalog No. M12351 CAS No. 1615713-87-5
A potent, noncovalent DprE1 inhibitor with IC50 of 43 nM, shows activity against Mycobacterium tuberculosis (Mtb) in vitro with MIC of 0.39 uM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 53 | In Stock |
|
5MG | 87 | In Stock |
|
10MG | 132 | In Stock |
|
25MG | 259 | In Stock |
|
50MG | 384 | In Stock |
|
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDprE1-IN-25
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, noncovalent DprE1 inhibitor with IC50 of 43 nM, shows activity against Mycobacterium tuberculosis (Mtb) in vitro with MIC of 0.39 uM.
-
DescriptionA potent, noncovalent DprE1 inhibitor with IC50 of 43 nM, shows activity against Mycobacterium tuberculosis (Mtb) in vitro with MIC of 0.39 uM.
-
SynonymsMDK3875; MDK-3875; MDK 3875; DprE1-IN-2; DprE1IN2
-
PathwayGPCR/G Protein
-
TargetAntibacterial
-
RecptorDprE
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1615713-87-5
-
Formula Weight368.43
-
Molecular FormulaC19H24N6O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 33 mg/mL
-
SMILESO=C(C1=CN(CC2=NC=NC(N(C)C)=C2C)C3=CC(C)=CN=C31)NCCO
-
Chemical Name1H-Pyrrolo[3,2-b]pyridine-3-carboxamide, 1-[[6-(dimethylamino)-5-methyl-4-pyrimidinyl]methyl]-N-(2-hydroxyethyl)-6-methyl-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Shirude PS, et al. J Med Chem. 2014 Jul 10;57(13):5728-37.
molnova catalog
related products
-
Walrycin-B
A novel baterial WalR response regulator; simultaneously affects the expression of WalR regulon genes.
-
Tizoxanide
Tizoxanide is the main metabolite of nitazoxanide, which is a synthetic nitrothiazolyl-salicylamide derivative and an antiprotozoal agent.
-
Taniborbactam
Taniborbactam is a novel beta-lactamase inhibitor for the treatment of bacterial infections.